Adds purified corticotropin gel and corticotropin zinc hydroxide to its portfolio
ANI Pharmaceuticals Inc.
has completed the acquisition of the NDAs for purified corticotropin gel and corticotropin zinc hydroxide from Merck
for $75 million in cash and a percentage of future net sales. The assets were acquired from a Dutch subsidiary of Merck by ANI Pharmaceuticals C.V., a Netherlands-based wholly owned indirect subsidiary of ANI.
Arthur Przybyl, president and chief executive officer, ANI Pharmaceuticals said, “Having now closed the acquisition of the corticotrophin NDAs, we look forward to advancing our re-commercialization plan.”